EGFR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of EGFR. The page also collects GeneMedi's different modalities and formats products for EGFR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the EGFR target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm which contributes to a severe form of Coronavirus Disease 2019 (COVID-19) resulting from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). [provided by RefSeq, Jul 2020]

Pre-made EGFR-specific INN-index biosimilar (antibody&conjugates)-cetuximab sarotalocan, Cetuximab, Amivantamab, Panitumumab, Losatuxizumab, Futuximab, depatuxizumab mafodotin, Etevritamab, losatuxizumab vedotin, Nimotuzumab, Necitumumab, Bafisontamab, Pimurutamab, Depatuxizumab, Modotuximab, Petosemtamab, Serclutamab, laprituximab emtansine, Zatuximab, Imgatuzumab, Laprituximab, Demupitamab, serclutamab talirine, Matuzumab, Zalutumumab, Tomuzotuximab

Anti-EGFR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-INN-777	Pre-Made Cetuximab Sarotalocan Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate	cetuximab sarotalocan		EGFR	Whole mAb ADC
GMP-Bios-ab-102	Pre-Made Cetuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Cetuximab		EGFR	Whole mAb
GMP-Bios-ab-021	Pre-Made Amivantamab biosimilar, Bispecific mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody	Amivantamab		EGFR;MET	Bispecific mAb
GMP-Bios-ab-425	Pre-Made Panitumumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Panitumumab		EGFR	Whole mAb
GMP-Bios-ab-324	Pre-Made Losatuxizumab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Losatuxizumab		EGFR	Whole mAb ADC
GMP-Bios-ab-227	Pre-Made Futuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Futuximab		EGFR	Whole mAb
GMP-Bios-INN-801	Pre-Made Depatuxizumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate	depatuxizumab mafodotin		EGFR	Whole mAb ADC
GMP-Bios-ab-197	Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibody	Etevritamab		EGFR;CD3E	Bispecific scFv
GMP-Bios-INN-900	Pre-Made Losatuxizumab Vedotin Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate	losatuxizumab vedotin		EGFR	Whole mAb ADC
GMP-Bios-ab-377	Pre-Made Nimotuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Nimotuzumab		EGFR	Whole mAb
GMP-Bios-ab-371	Pre-Made Necitumumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Necitumumab		EGFR	Whole mAb
GMP-Bios-ab-656	Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody	Bafisontamab		EGFR;MET	Bispecific Mixed mAb and Fab
GMP-Bios-ab-443	Pre-Made Pimurutamab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Pimurutamab		EGFR	Whole mAb
GMP-Bios-ab-141	Pre-Made Depatuxizumab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Depatuxizumab		EGFR	Whole mAb ADC
GMP-Bios-ab-353	Pre-Made Modotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Modotuximab	Zatuximab	EGFR	Whole mAb
GMP-Bios-ab-440	Pre-Made Petosemtamab biosimilar, Bispecific mAb, Anti-EGFR;LGR5 Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;FEX/GPR49/GPR67/GRP49/HG38 therapeutic antibody	Petosemtamab		EGFR;LGR5	Bispecific mAb
GMP-Bios-ab-513	Pre-Made Serclutamab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Serclutamab		EGFR	Whole mAb ADC
GMP-Bios-INN-884	Pre-Made Laprituximab Emtansine Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate	laprituximab emtansine		EGFR	Whole mAb ADC
GMP-Bios-ab-642	Pre-Made Zatuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Zatuximab	modotuximab	EGFR	Whole mAb
GMP-Bios-ab-268	Pre-Made Imgatuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Imgatuzumab		EGFR	Whole mAb
GMP-Bios-ab-296	Pre-Made Laprituximab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Laprituximab		EGFR	Whole mAb ADC
GMP-Bios-ab-138	Pre-Made Demupitamab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Demupitamab		EGFR	Whole mAb
GMP-Bios-INN-988	Pre-Made Serclutamab Talirine Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate	serclutamab talirine		EGFR	Whole mAb ADC
GMP-Bios-ab-337	Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Matuzumab		EGFR	Whole mAb
GMP-Bios-ab-637	Pre-Made Zalutumumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Zalutumumab		EGFR	Whole mAb
GMP-Bios-ab-586	Pre-Made Tomuzotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody	Tomuzotuximab		EGFR	Whole mAb

Pre-made anti-EGFR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-EGFR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-EGFR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T59328-Ab	Anti-EGFR monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody